| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2018-11-15 |
| タイトル |
|
|
タイトル |
Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ozaki, Yuki
Koide, Masanori
Furuya, Yuriko
Ninomiya, Tadashi
Yasuda, Hisataka
Nakamura, Midori
Kobayashi, Yasuhiro
Takahashi, Naoyuki
Yoshinari, Nobuo
Udagawa, Nobuyuki
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL. RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL to RANK, a cellular receptor of RANKL. OPG-deficient (OPG–/–) mice exhibit severe alveolar bone loss with enhanced bone resorption. WP9QY (W9) peptide binds to RANKL and blocks RANKL-induced osteoclastogenesis. W9 is also reported to stimulate bone formation in vivo. Here, we show that treatment with W9 restores alveolar bone loss in OPG–/–mice by suppressing osteoclastogenesis and enhancing osteoblastogenesis. Administration of W9 or risedronate, a bisphosphonate, to OPG–/–mice significantly decreased the osteoclast number in the alveolar bone. Interestingly, treatment with W9, but not risedronate, enhanced Wnt/β-catenin signaling and induced alveolar bone formation in OPG–/–mice. Expression of sclerostin, an inhibitor of Wnt/β-catenin signaling, was significantly lower in tibiae of OPG–/–mice than in wild-type mice. Treatment with risedronate recovered sclerostin expression in OPG–/–mice, while W9 treatment further suppressed sclerostin expression. Histomorphometric analysis confirmed that bone formation-related parameters in OPG–/–mice, such as osteoblast number, osteoblast surface and osteoid surface, were increased by W9 administration but not by risedronate administration. These results suggest that treatment of OPG–/–mice with W9 suppressed osteoclastogenesis by inhibiting RANKL signaling and enhanced osteoblastogenesis by attenuating sclerostin expression in the alveolar bone. Taken together, W9 may be a useful drug to prevent alveolar bone loss in periodontitis. |
| 書誌情報 |
en : PLoS One
巻 12,
号 9,
p. e0184904,
発行日 2017-09-22
|
| 出版者 |
|
|
出版者 |
Public Library of Science |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1932-6203 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1371/journal.pone.0184904 |
|
|
関連名称 |
info:doi/10.1371/journal.pone.0184904 |
| 権利 |
|
|
権利情報 |
Copyright: © 2017 Ozaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| 情報源 |
|
|
|
関連名称 |
雑誌掲載論文(電子版) |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609750/ |
|
|
関連名称 |
PubMed Central® (PMC) |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184904 |
|
|
関連名称 |
PLOS One |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
本文 (1.2 MB)
.png)
